Price Target Changed • Aug 05
Price target decreased by 24% to €1.80 Down from €2.38, the current price target is provided by 1 analyst. New target price is 129% above last closing price of €0.79. Stock is down 2.1% over the past year. The company is forecast to post a net loss per share of €0.23 next year compared to a net loss per share of €0.47 last year. Announcement • Jul 24
Valbiotis Publishes Results of Reverse-It Clinical Study Evaluating Totum 63 in Nature Communications Valbiotis announced the publication of the results of the REVERSE-IT clinical study evaluating Totum 63 in the international scientific journal Nature Communications; This publication represents a major milestone for Totum•63 and marks significant scientific recognition of the REVERSE-IT clinical trial by a leading international journal renowned for its editorial and methodological rigor. Articles published in Nature Communications undergo a rigorous peer-review process based in particular on the robustness of the data, the quality of the clinical design and the scientific importance of the results. This publication thus provides independent validation of the results obtained with Totum 63 and strengthens their credibility within the international scientific and medical community. Open-access publication will also allow broad dissemination of the results among researchers, clinicians and institutions involved in metabolic prevention and the early management of type 2 diabetes. Prior to this publication, the REVERSE-IT results had already been selected for an oral communication at the 84th ADA Scientific Sessions 2024 and then chosen for a presentation at the EASD Annual Meeting 2024, illustrating the growing interest of the international scientific community in this study. This succession of milestones — oral communication at the ADA, selection at the EASD and then publication in Nature Communications — illustrates the progressive recognition of the REVERSE-IT results by several leading international scientific bodies. REVERSE-IT is a randomized, placebo-controlled, multicenter clinical trial conducted over 24 weeks in 636 participants with prediabetes or recently diagnosed type 2 diabetes not requiring immediate antidiabetic treatment. The study was conducted in 52 centers across 7 European countries, strengthening the methodological robustness, the representativeness of the study population and the international scope of the results obtained. Participants, aged 18 to 70 years, had a BMI between 25 and 40 kg/m² as well as high abdominal adiposity, corresponding to a population at increased cardiometabolic risk. Participants were randomized into three groups: placebo; Totum 63: 5 g/day in 2 intakes and Totum 63: 5 g/day in 3 intakes. All groups also received standard lifestyle and dietary recommendations. Totum 63 is a plant-based active substance rich in polyphenols, composed of a blend of biomolecules derived from five plant extracts. The REVERSE-IT study shows a significant reduction in fasting blood glucose after 6 months with Totum 63, corresponding to the study's primary endpoint. The two-daily-intake regimen showed results consistent with those observed with three intakes per day, allowing different dosing schemes to be considered. Beyond the primary endpoint, the results also highlight favorable effects on several cardiometabolic parameters associated with the risk of progression to type 2 diabetes, including: HbA1c (glycated hemoglobin); 2-hour blood glucose; insulin resistance (HOMA-IR); body weight; the lipid profile and low-grade inflammation. The study also reports a reduction in the percentage of participants showing a deterioration of glycemic status, in particular a progression from prediabetes to type 2 diabetes. These results suggest an overall cardiometabolic benefit of Totum•63 beyond glycemic control alone. Totum 63 showed a favorable tolerability profile with no particular safety signal observed in the REVERSE-IT study. Reported compliance reached 97% across all groups, an important element for the clinical interpretation of the results in a population managed over the long term. Major Estimate Revision • Jul 01
Consensus EPS estimates upgraded to €0.31 loss The consensus outlook for fiscal year 2026 has been updated. 2026 losses forecast to reduce from -€0.377 to -€0.312 per share. Revenue forecast unchanged from €3.85m at last update. Biotechs industry in France expected to see average net income growth of 7.1% next year. Consensus price target down from €2.38 to €2.23. Share price fell 7.1% to €0.79 over the past week. 
